

August 28, 2025

PRIOR AUTHORIZATION UPDATES FOR STAR, D-SNP, AND MARKETPLACE EFFECTIVE NOVEMBER 1, 2025

SUMMARY OF NOTIFICATION

On November 1, 2025, the following updates will be in effect:

1. The following code will be added to the prior authorization catalog for **STAR** and **D-SNP**.
 - J0174 Injection, lecanemab-irmb, 1 mg (Leqembi)
2. The following codes will be added to the prior authorization catalog for **Marketplace**.
 - J0174 Injection, lecanemab-irmb, 1 mg (Leqembi)
 - J0175 In Injection, donanemab-azbt, 2 mg (Kisunla)
3. We will also be implementing newly established Medical Review Guidelines (MRGs) for lecanemab-irmb (Leqembi), donanemab-azbt (Kisunla) and pegloticase (Krystexxa) in **Marketplace** and **D-SNP**.

KEY DETAILS

Please refer to our [Community provider website](#) for the complete November 1, 2025 prior authorization catalog.

For the newly established Medical Review Guidelines (MRGs), you can view the updates under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section. The Leqembi, Kisunla and Krystexxa MRGs specify clinical criteria required to be met for the products’ approval.